Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FKAP5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $63,175.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. This delivery order was issued without a set-aside designation under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The ultimate completion date for this delivery order is December 22, 2025, with an award date of December 1, 2025. MACI (matrix-applied characterized autologous mesenchymal cells) implants are specialized orthopedic products used in cartilage repair and regeneration therapies within military medical facilities.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's global healthcare supply chain under the broader $30.3 billion PPV-G GEN V acquisition strategy. The company's parent Indefinite Delivery Contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders and its comprehensive product portfolio spanning specialty pharmaceuticals, biologics, vaccines, and surgical products demonstrate its capability to fulfill diverse medical supply requirements for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FKAP5?
SPE2DR26FKAP5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FKAP5 worth?
The government has obligated $63,176 on SPE2DR26FKAP5.
Is contract SPE2DR26FKAP5 an order under another contract?
Yes. SPE2DR26FKAP5 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAP5 competed?
The extent of competition for SPE2DR26FKAP5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award